Tenpoint Therapeutics Launches With $70 Million Series A Financing To Reverse Vision Loss Through Engineered Cell-Based Therapeutics And In Vivo Reprogramming
Amount Raised
$70 Million
Round Type
Series A
Investors
Description
Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases, today announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. The Series A round included new investment from British Patient Capital as well as funding from all seed investors including F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund among others. F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
Quick answer
Tenpoint Therapeutics raised $70 Million in a Series A round, dated July 12, 2023. Investors: F Prime, UCL Technology Fund, Eight Roads, Qiming Venture Partners USA, Sofinnova Partners, F Prime Capital and British Patient Capital.
- How much did Tenpoint Therapeutics raise?
- Tenpoint Therapeutics raised $70 Million in a Series A round on July 12, 2023.
- Who invested in Tenpoint Therapeutics?
- F Prime, UCL Technology Fund, Eight Roads, Qiming Venture Partners USA, Sofinnova Partners, F Prime Capital and British Patient Capital are named as investors in this round.
- What does Tenpoint Therapeutics do?
- Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts..
- Where is Tenpoint Therapeutics based and how big is it?
- Fundz records about 25 employees.
- Who are the decision-makers at Tenpoint Therapeutics?
- Fundz holds 1 contact at Tenpoint Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Tenpoint Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Fore Biotherapeutics raised $75M (Series D) on August 24, 2023.
- Rapport raised $150M (Series B) on August 24, 2023.
- Actimed Therapeutics raised $6.1M (Series A) on August 22, 2023.
- Abcuro raised $155M (Series B) on August 17, 2023.
- Abcuro raised $120M on August 11, 2023.
- MindMed raised $7M on August 11, 2023.
Who to call at Tenpoint Therapeutics, and when
A new round usually means Tenpoint Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tenpoint Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tenpoint Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tenpoint Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tenpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTenpoint Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.